



Resources for TIR Monoclonal Antibody Disaster Reporting

Resources for COVID-19 Reporting

- Data exchange specifications will soon be available on our DSHS website.
- Information for COVID-19 Vaccination Providers
<https://www.dshs.texas.gov/coronavirus/immunize/provider-information.aspx>
- How to report disaster immunizations to ImmTrac2
<https://www.youtube.com/playlist?list=PL7xet9qFzOjVAa7qCZEHUIE0LtZJyxNVs>

Resources for Clinicians – Monoclonal Antibody Treatment

- COVID-19 Monoclonal Antibody Eligibility Checklist – Treatment and Post Exposure Prophylaxis
<https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/mAb-eligibility-treatment-and-post-exposure-prophylaxis.aspx>
- COVID-19 Monoclonal Antibody Checklist for Subcutaneous and Intravenous Administration
<https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/COVID19-mAb-checklist-subcutaneous-intravenous-administration.aspx>
- Subcutaneous Injection Instructions
<https://www.phe.gov/emergency/events/COVID19/therapeutics/Documents/REGEN-COV-SubQ-FactSheet-July2021-508.pdf>
- EMS Template Protocol
<https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/EMS-Template-Protocol-for-COVID19-mAbs-Administration.aspx>



- Guides on Vaccination after Monoclonal Antibody Treatment administration

<https://www.cdc.gov/vaccines/COVID-19/clinical-considerations/COVID-19-vaccines-us.html>

Ordering Instructions for COVID-19 Therapeutics

- Step-by-step instructions for placing a COVID-19 therapeutic order in VAOS

<https://www.dshs.Texas.gov/immunize/COVID19/COVID-19-Therapeutics-Job-Aid.pdf>

COVID-19 Support Line

- Call 833-832-7068, option "0" (zero) from 8:00 am – 5:00 pm Monday through Friday.



Specifications for Electronic Data Exchange

Registered – Exchanging Data

If your organization is registered and is exchanging data:

- Utilize your existing method of reporting data to the Registry.
- Resolve any existing data quality errors preventing your data from being accepted.
- Antiviral, Immunization, or Medication (AIM) information must be entered into your electronic health records (EHR) system to report to the Registry.

Registered – Not Exchanging Data

If your organization is registered and is not exchanging data, you must submit a Registration of Intent (ROI):

- ROI informs the registry of your readiness to begin data exchange.
- Captures key information about your organization and EHR vendor.
- Allows us to setup a data exchange account for your organization.
- The data exchange account is used to report AIMs electronically.

Reporting COVID-19 Immunizations

- Use approved CVX or NDC codes provided by the CDC.
 - <https://www.cdc.gov/vaccines/programs/iis/code-sets.html>.
- Work with your EHR vendor to ensure information is entered correctly.
- Report administrations via existing data exchange methods.
- Report vaccine lot number accurately.
- Daily submissions required for COVID data.
- Identify and resolve any data quality issues timely.



Reporting COVID-19 Other Medications

- Reporting of disaster related antivirals or other medications via data exchange require EHR changes to HL7 specifications, specifically RXA-5.
- RXA-5 must be conformed as follows to be accepted:
 - RXA-5.1 - Name of the antiviral or other medication. This value is determined by the registry.
 - RXA-5.2 – Description of the antiviral or other medication.
 - RXA-5.3 – Tradename Indicator = WVTN. This value must be used. WVTN indicates the data reported is the tradename instead of CVX or NDC Codes.
- RXA-17 – Manufacturer Code. This value is determined by the Registry.
- All other HL7 specifications for immunization reporting are required.
- When formatted correctly, our system produces an informational error, *IEE-103::Informational error. If supplied, RXA-5-3 should match constraint listed in spec, that may be ignored.*

Casirivimab and Imdevimab 300mg/2.5mL

To report these medications, RXA-5 and RXA-17 would be formatted as indicated below:

RXA|||||Casirivimab, 300mg/2.5mL^COVID19 Antiviral^WVTN|||||||REG|

RXA|||||Imdevimab, 300mg/2.5mL^COVID19 Antiviral^WVTN|||||||REG|

- Two RXA segments to report the medications that equal one dose.
- Tradenames must include specific dosage amounts.
- REG is the manufacturer code for Regeneron.

Casirivimab and Imdevimab 1332mg/11.1mL To report these medications, RXA-5 and RXA-17 would be formatted as indicated below:

RXA|||||Casirivimab, 1332mg/11.1mL^COVID19 Antiviral^WVTN|||||||REG|

RXA|||||Imdevimab, 1332mg/11.1mL^COVID19 Antiviral^WVTN|||||||REG|

- Two RXA segments to report the medications that equal one dose.
- Tradenames must include specific dosage amounts.
- REG is the manufacturer code for Regeneron.

REGEN-COV (Casirivimab 600mg and Imdevimab 600mg/10mL)

To report these medications, RXA-5 and RXA-17 would be formatted as indicated below:

RXA|||||61755-039-01^Regeneron Dose Pack 039^NDC|||||||REG|

- Regeneron Dose Pack 039 uses NDC for reporting.
- REG is the manufacturer code for Regeneron.

Bamlanivimab and Etesevimab Combined Treatment for Post-exposure Prophylaxis

To report these medications, please use the ImmTrac2 online application <https://immtrac.dshs.texas.gov/TXPRD/portalInfoManager.do>.

Resources for Electronic Data Exchange

The [Electronic Data Exchange Resource Guide](#) provides steps on submitting the ROI and other steps required to establish and maintain a data exchange connection with the Registry.

The [Texas Immunization Registry HL7 2.5.1 Implementation Guide](#) provides HL7 specifications to report patient and immunization information, including how to report trade names for AIMs.

These resources can be found on the DSHS website under the Forms and Document page at <https://www.dshs.texas.gov/immunize/immtrac/forms.shtm>.

We also have a good number of Data Exchange Recorded Webinars at our User Training webpage at <https://www.dshs.texas.gov/immunize/immtrac/User-Training/>. These webinars provide guidance on the steps for establishing and maintaining a data exchange connection with the Registry. The webinars have pre-recorded content, frequently asked questions we receive on the content and guidance on how to resolve most of the common issue we see related to the content.

One recorded webinar that is recommended for all COVID providers to watch and familiarize themselves with is titled "Data Quality and Error Resolution" and it can be found on our User Training webpage at <https://www.dshs.texas.gov/immunize/immtrac/User-Training/>.

This webinar addresses the top data quality issues we are seeing for COVID reporting whether reporting online or via data exchange. The webinar details how providers can resolve data quality issues for more accurate and timely reporting.

Our data exchange resource guides are found on our Forms and Documents page of our DSHS website at <https://www.dshs.texas.gov/immunize/immtrac/forms.shtm>.



Texas Immunization Registry

Our data exchange webinars and other videos are found on our User Training webpage at <https://www.dshs.texas.gov/immunize/immtrac/User-Training>.

Interoperability Team Contact Info

If you have questions about data exchange, contact the Registry's Interoperability Team at 800-348-9158, Option 3 or ImmTracMU@dshs.texas.gov.

To register as a COVID-19 provider use the Texas DSHS Immunization Program Portal: <https://enrolltexasiz.dshs.texas.gov/>.